Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 9/20 | 0.49 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225808 | 0.94 | SLC2A1 (0.49) | GABRA2GABRB2SLC2A1SLC2A2ALDH1A1 | |
| SCHEMBL1430117 | 0.86 | KCNK3 (0.52) | GABRB2 | |
| SCHEMBL1432945 | 0.85 | SLC2A1 (0.56) | CYP1A2CYP2C9CYP2C19GABRA2GABRB2 | |
| SCHEMBL4324580 | 0.84 | SLC2A1 (0.53) | GABRA2GABRB2SLC2A1ALDH1A1 | |
| SCHEMBL2178544 | 0.84 | ALDH1A1 (0.49) | GABRA2GABRB2SLC2A1SLC2A2ALDH1A1 | |
| SCHEMBL1427429 | 0.83 | KDM4E (0.52) | GABRA2GABRB2SLC2A1ALDH1A1HPGD | |
| SCHEMBL1430312 | 0.82 | GABRA1 (0.53) | GABRA2GABRB2SLC2A1ALDH1A1HPGD | |
| SCHEMBL2180865 | 0.82 | SLC2A1 (0.49) | GABRA2GABRB2SLC2A1SLC2A2ALDH1A1 | |
| SCHEMBL2178982 | 0.82 | TSPO (0.46) | GABRA2GABRB2SLC2A1ALDH1A1GAA | |
| SCHEMBL15346997 | 0.82 | SLC2A2 (0.40) | SLC2A1SLC2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | CYP1A2 61/4885CYP2C9 185/4885CYP2C19 91/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | CYP1A2 61/4885CYP2C9 185/4885CYP2C19 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.